Novel α7 nicotinic acetylcholine receptor modulators as potential antitussive agents

Area of Science:

• Pharmacology
• Neuroscience
• Medicinal Chemistry

Background:

• Cough is a common symptom with limited non-narcotic treatment options.
• Alpha-7 nicotinic acetylcholine receptor (nAChR) pathways are implicated in modulating cough reflexes.
• Development of targeted therapies for cough remains a significant unmet medical need.

Purpose of the Study:

• To design and evaluate novel alpha-7 nAChR modulators for antitussive activity.
• To assess the efficacy of a lead compound (Compound 16) in a preclinical cough model.
• To explore different routes of administration for potential therapeutic application.

Main Methods:

• Synthesis and in vitro characterization of a novel series of alpha-7 nAChR modulators.
• In vivo evaluation of antitussive activity using a chemically induced cough model in guinea pigs.
• Comparison of efficacy with a positive control (codeine) and assessment across intraperitoneal, oral, and inhaled administration routes.

Main Results:

• Compound 16 demonstrated significant dose-dependent reduction in cough frequency compared to vehicle control (p < 0.01).
• The efficacy of Compound 16 was comparable to codeine (30 mg/kg) at tested doses.
• Inhaled administration of Compound 16 showed significant antitussive effects at a low dose of 0.4 mg/kg (p < 0.05).

Conclusions:

• Novel alpha-7 nAChR modulators possess significant antitussive properties.
• Compound 16 represents a promising candidate for cough suppression.
• Alpha-7 nAChR modulation offers a potential non-narcotic therapeutic strategy for acute and chronic cough.